But for perimenopausal and postmenopausal women, where adipose tissue becomes an increasingly important estrogen contributor, rapid fat loss can push estrogen levels low enough to cause symptoms
Research Profile Mechanism of Action (Triple Agonist): Retatrutide is a single peptide chain that simultaneously activates three distinct receptors: GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and GCGR (Glucagon Receptor)
As a triple agonist with superior weight loss data, it may command a premium over existing dual agonists
CagriSema vs Retatrutide is one of the most important next-generation obesity peptide comparisons going into 2026
6 months Life-changing results
Currently approved and commonly used GLP-1R agonists include exenatide (the synthetic form of Ex-4, a naturally occurring GLP-1R agonist), lixisenatide, dulaglutide liraglutide and semaglutide ( Figure 2 ) ( Figure 2 Exenatide, a peptide of 39 amino acids, has a much slower metabolism than endogenous GLP-1 (half-life of 3-4 h) (119, 120)
